A phosphodiesterase 5 inhibitor indicated for treatment of erectile dysfunction.
Administration with any form of organic nitrates is contraindicated as it may potentiate hypotension.
May augment the vasodilatory properties of other antihypertensive medications.
Metabolism is principally mediated by the CYP 450 isoform 3A4 (CYP3A4).
Should not be used with concomitant strong CYP3A4 inhibitors.
The maximum recommended dose is 50 mg in patients with moderate CYP3A4 inhibitors, and not to exceed once every 24 hours.
Maybe associated with priapism.
Maybe associated with sudden loss of vision in one or both eyes, and this may be a sign of nonarteritic anterior ischemic optic neuropathy.
Sudden decrease in hearing or hearing loss, tinnitus or dizziness.
Caution is advised when coadministered with Alpha blockers which may increase the risk of symptomatic hypotension.
Significant consumption of alcohol may potentiate hypotension.